Kazia Therapeutics Limited (KZIA)
 NASDAQ: KZIA · Real-Time Price · USD
 7.68
 -0.01 (-0.13%)
  At close: Oct 30, 2025, 4:00 PM EDT
7.67
 -0.01 (-0.13%)
  Pre-market: Oct 31, 2025, 5:43 AM EDT
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 22.29K AUD in the half year ending December 31, 2024. This brings the company's revenue in the last twelve months to 2.50M, up 248,983.08% year-over-year. In the fiscal year ending June 30, 2024, Kazia Therapeutics had annual revenue of 2.48M with 248,000.00% growth.
Revenue (ttm) 
 2.50M AUD
Revenue Growth 
 +248,983.08%
P/S Ratio 
 3.53
Revenue / Employee 
 192,560 AUD
Employees 
 13
Market Cap 
8.59M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% | 
| Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% | 
| Jun 30, 2022 | 10.00K | -15.17M | -99.93% | 
| Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% | 
| Jun 30, 2020 | 988.11K | -451.89K | -31.38% | 
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
KZIA News
- 4 days ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire
- 24 days ago - Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - PRNewsWire
- 4 weeks ago - Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - PRNewsWire
- 4 weeks ago - Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - PRNewsWire
- 3 months ago - Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - PRNewsWire
- 4 months ago - Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - PRNewsWire
- 5 months ago - Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) - PRNewsWire